1-(4-溴丁氧基)-4-氯苯 | 2033-81-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(4-溴丁氧基)-4-氯苯
• 英文名称: 1-(4-bromobutoxy)-4-chlorobenzene
• 英文别名: 4-(4-chlorophenoxy)butyl bromide
• CAS: 2033-81-0
• 化学式: C₁₀H₁₂BrClO
• 分子量: 263.562
• InChiKey: DPTVPYBSBNIACI-UHFFFAOYSA-N

物化性质

• 熔点：
  30-31 °C
• 沸点：
  159-161 °C (9 mmHg)
• 密度：
  1.401±0.06 g/cm3(Predicted)
• 闪点：
  160 °C

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/22,R36/37/38
• 海关编码：
  2909309090
• 储存条件：
  室温

SDS

Name:	1-(4-Bromobutoxy)-4-chlorobenzene Material Safety Data Sheet
Synonym:
CAS:	2033-81-0

Section 1 - Chemical Product MSDS Name:1-(4-Bromobutoxy)-4-chlorobenzene Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2033-81-0	1-(4-Bromobutoxy)-4-chlorobenzene		unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2033-81-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 159 - 161 deg C @9mmHg
Freezing/Melting Point: 30 - 31 deg C
Autoignition Temperature: Not available.
Flash Point: 160 deg C ( 320.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >180 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12BrClO
Molecular Weight: 263.56

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2033-81-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Bromobutoxy)-4-chlorobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 2033-81-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2033-81-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2033-81-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-溴丁氧基)-4-氯苯 在 potassium carbonate 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 24.0h， 生成 [3-[4-(4-chlorophenoxy)butoxy]phenyl] N-methylcarbamate
  参考文献：
  名称：

  新型氨基甲酸酯衍生物的合成和杀虫活性作为潜在的双结合位点乙酰胆碱酯酶抑制剂

  摘要：

  在生物系统中，与单价配体相比，二价配体通常对其受体具有增强的功能亲和力。基于乙酰胆碱酯酶（AChE）的结构，设计并合成了一系列新型氨基甲酸酯异二仿衍生物，旨在提高其对AChE抑制的能力。使用从家蝇大脑中获得的AChE测试了所有新化合物的AChE抑制能力。生物测定结果表明，与母体苯基N相比，化合物6j，6k，6m，6n，6p和6q具有更高的抑制活性。-浓度为100 mg / L的氨基甲酸甲酯（MH）。其中，这些化合物中最有效的AChE抑制剂为6q（IC 50 = 12μM），与MH相比，其AChE抑制活性高62倍，与灭多威（MT）相比，活性高12倍。化合物6q的3-硝基苯氧基部分能够与峡谷内的芳族氨基酸残基相互作用，并且苯基N-甲基氨基甲酸酯部分能够与AChE的催化位点同时相互作用。化合物6j，6k，6m，6n，6p和6q的杀虫活性被进一步评估。与体外生物测定结果一致，在300 mg / L

  DOI：

  10.1021/jf1032284
• 作为产物：
  描述：

  1,4-二溴丁烷 、 对氯苯酚 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 12.0h， 以95%的产率得到1-(4-溴丁氧基)-4-氯苯
  参考文献：
  名称：

  镍催化未活化烷基溴化物的还原酰胺化

  摘要：

  本文介绍了一种易于使用的镍催化的未活化伯，仲和叔烷基溴化物与异氰酸酯的镍催化还原酰胺化反应。这种催化策略可在温和条件下高效合成各种脂族酰胺，并具有出色的化学选择性，同时避免使用化学计量的和敏感的有机金属试剂。

  DOI：

  10.1002/anie.201605162

文献信息

• Visible-Light-Driven Palladium-Catalyzed Radical Alkylation of C−H Bonds with Unactivated Alkyl Bromides
  作者：Wen-Jun Zhou、Guang-Mei Cao、Guo Shen、Xing-Yong Zhu、Yong-Yuan Gui、Jian-Heng Ye、Liang Sun、Li-Li Liao、Jing Li、Da-Gang Yu

  DOI：10.1002/anie.201704513

  日期：2017.12.4

  Reported herein is a novel visible‐light photoredox system with Pd(PPh3)4 as the sole catalyst for the realization of the first direct cross‐coupling of C(sp3)−H bonds in N‐aryl tetrahydroisoquinolines with unactivated alkyl bromides. Moreover, intra‐ and intermolecular alkylations of heteroarenes were also developed under mild reaction conditions. A variety of tertiary, secondary, and primary alkyl

  本文报道了一种新型的可见光光氧化还原体系，其中Pd（PPh 3）4是实现N-芳基四氢异喹啉中C（sp 3）-H键与未活化烷基溴的第一个直接交叉偶联的唯一催化剂。此外，杂芳烃的分子内和分子间烷基化反应也在温和的反应条件下进行。各种叔，仲和伯烷基溴经过反应生成C（sp 3）-C（sp 3）和C（sp 2）-C（sp 3）债券，收益率中等至极高。这些氧化还原中性反应具有广泛的底物范围（> 60个示例），良好的功能基团耐受性和易于生成的四元中心。机理研究表明，简单的钯配合物充当可见光光催化剂，自由基参与该过程。
• Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives.
  作者：TAKASHI SOHDA、KATSUTOSHI MIZUNO、EIKO IMAMIYA、YASUO SUGIYAMA、TAKESHI FUJITA、YUTAKA KAWAMATSU

  DOI：10.1248/cpb.30.3580

  日期：——

  More than 100 5-substituted thiazolidine-2, 4-diones were prepared and their hypoglycemic and hypolipidemic activities were evaluated with genetically obese and diabetic mice, yellow KK. The structure-activity relationship study showed that the 5-(4-oxybenzyl) moiety is essential for substantial activity. Among these compounds, 5-(4-cyclohexylmethoxy) benzylthiazolidine-2, 4-dione (47), 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2, 4-dione (49, ADD-3878) and 5-4-[2-(3-pyridyl) ethoxy] benzyl} thiazolidine-2, 4-dione (59) exhibited the most favorable properties in terms of activity and toxicity.

  合成了100多种5-取代的噻唑烷-2,4-二酮类化合物，并通过遗传性肥胖和糖尿病小鼠（KK黄色小鼠）评估了它们的降血糖和降血脂活性。结构-活性关系研究表明，5-(4-羟基苄基)部分对于显著活性是必要的。在这些化合物中，5-(4-环己基甲氧基)苄基噻唑烷-2,4-二酮（47）、5-[4-(1-甲基环己基甲氧基)苄基]-噻唑烷-2,4-二酮（49，ADD-3878）和5-4-[2-(3-吡啶基)乙氧基]苄基}噻唑烷-2,4-二酮（59）在活性和毒性方面表现出最佳特性。
• Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases
  作者：Alexander Schmitz、Ananthakrishnan Sankaranarayanan、Philippe Azam、Kristina Schmidt-Lassen、Daniel Homerick、Wolfram Hänsel、Heike Wulff

  DOI：10.1124/mol.105.015669

  日期：2005.11

  The lymphocyte K+ channel Kv1.3 constitutes an attractive pharmacological target for the selective suppression of terminally differentiated effector memory T (TEM) cells in T cell-mediated autoimmune diseases, such as multiple sclerosis and type 1 diabetes. Unfortunately, none of the existing small-molecule Kv1.3 blockers is selective, and many of them, such as correolide, 4-phenyl-4-[3-(methoxyphenyl)-3-oxo-2-azapropyl]cyclohexanone, and our own compound Psora-4 inhibit the cardiac K+ channel Kv1.5. By further exploring the structure-activity relationship around Psora-4 through a combination of traditional medicinal chemistry and whole-cell patch-clamp, we identified a series of new phenoxyalkoxypsoralens that exhibit 2- to 50-fold selectivity for Kv1.3 over Kv1.5, depending on their exact substitution pattern. The most potent and “drug-like” compound of this series, 5-(4-phenoxybutoxy)psoralen (PAP-1), blocks Kv1.3 in a use-dependent manner, with a Hill coefficient of 2 and an EC50 of 2 nM, by preferentially binding to the C-type inactivated state of the channel. PAP-1 is 23-fold selective over Kv1.5, 33- to 125-fold selective over other Kv1-family channels, and 500- to 7500-fold selective over Kv2.1, Kv3.1, Kv3.2, Kv4.2, HERG, calcium-activated K+ channels, Na+,Ca2+, and Cl- channels. PAP-1 does not exhibit cytotoxic or phototoxic effects, is negative in the Ames test, and affects cytochrome P450-dependent enzymes only at micromolar concentrations. PAP-1 potently inhibits the proliferation of human TEM cells and suppresses delayed type hypersensitivity, a TEM cell-mediated reaction, in rats. PAP-1 and several of its derivatives therefore constitute excellent new tools to further explore Kv1.3 as a target for immunosuppression and could potentially be developed into orally available immunomodulators.

  淋巴细胞K+通道Kv1.3是选择性抑制T细胞介导的自身免疫性疾病（如多发性硬化症和1型糖尿病）中终末分化效应记忆T（TEM）细胞的有吸引力的药理学靶点。不幸的是，目前存在的所有小分子Kv1.3阻断剂均不具备选择性，其中许多如柯里奥利德、4-苯基-4-[3-(甲氧苯基)-3-酮-2-氮杂丙基]环己酮以及我们自己的化合物Psora-4均可抑制心脏K+通道Kv1.5。通过结合传统药物化学和全细胞膜片钳技术进一步探索Psora-4的构效关系，我们鉴定了一系列新的苯氧烷氧基补骨脂素，它们对Kv1.3的选择性比Kv1.5高2至50倍，具体取决于其取代模式。这一系列化合物中，最具有强效和“类药物”性质的化合物为5-(4-苯氧基丁氧基)补骨脂素（PAP-1），它以使用依赖性方式阻断Kv1.3，Hill系数为2，EC50为2 nM，通过优先结合通道的C型失活态。PAP-1对Kv1.5的选择性为23倍，对其他Kv1家族通道的选择性为33至125倍，对Kv2.1、Kv3.1、Kv3.2、Kv4.2、HERG、钙激活K+通道、Na+、Ca2+及Cl-通道的选择性为500至7000倍。PAP-1无细胞毒性或光毒性，Ames试验呈阴性，对细胞色素P450依赖性酶的影响仅在微摩尔浓度下显现。PAP-1能强效抑制人TEM细胞的增殖并抑制大鼠中的迟发型超敏反应（一种TEM细胞介导的反应）。因此，PAP-1及其若干衍生物构成了探索Kv1.3作为免疫抑制靶点的新工具，并有可能开发成口服可用的免疫调节剂。
• [EN] MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY<br/>[FR] INHIBITEURS DE LA MONOACYLGLYCÉROL LIPASE DE MODULATION DE L'ACTIVITÉ CANNABINOÏDE
  申请人：UNIV NORTHEASTERN

  公开号：WO2009052319A1

  公开（公告）日：2009-04-23

  Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.

  揭示了抑制单酰基甘油脂酶（MGL）和脂肪酸酰胺水解酶（FAAH）作用的化合物和组合物，抑制MGL和FAAH的方法，调节大麻素受体的方法，以及治疗与调节大麻素受体相关的各种疾病的方法。
• Chitosan–silica sulfate nanohybrid: a highly efficient and green heterogeneous nanocatalyst for the regioselective synthesis of N-alkyl purine, pyrimidine and related N-heterocycles via presilylated method
  作者：Somayeh Behrouz、Mohammad Navid Soltani Rad、Mohammad Amin Piltan

  DOI：10.1007/s11696-019-00863-1

  日期：2020.1

  pyrimidine nucleobases as well as other related N-heterocycles with HMDS utilizing chitosan–silica sulfate nanohybrid (CSSNH) is described. CSSNH is proved to be a useful, highly efficient and eco-friendly heterogeneous nanohybrid catalyst for silylation of nucleobases. The presilylated nucleobases then underwent the reaction with different sources of carbon electrophiles to afford the desired N-alkyl-substituted

  摘要描述了利用壳聚糖-硫酸硅纳米杂化物（CSSNH）用HMDS对嘌呤和嘧啶核苷碱基以及其他相关的N-杂环进行甲硅烷基化。事实证明，CSSNH是一种有用，高效且生态友好的异质纳米杂化催化剂，可用于核碱基的甲硅烷基化。然后使预甲硅烷基化的核碱基与不同来源的碳亲电试剂反应，以良好至优异的产率得到所需的N-烷基取代的衍生物。CSSNH展示了一些优势，包括易于处理和准备，低成本，可重复使用性以及对环境的友好性。这些独特的特性使CSSNH成为绿色工业过程中的理想选择。 图形摘要